WEBINAR | MRD-Driven Oncology Trials: Regulatory, Clinical and Pharmacology Considerations
Minimal residual disease (MRD) is rapidly becoming a critical biomarker in oncology drug development, enabling earlier insights into therapeutic activity, more precise patient stratification and more efficient clinical trial design. In this on-demand webinar, Syneos Health experts explore how sponsors can strategically integrate MRD across early-phase and registrational oncology programs. The discussion highlights how MRD can support dose selection, cohort expansion decisions and proof-of-concept evaluation—while aligning with evolving regulatory expectations.
The session also addresses key operational and scientific considerations, including assay sensitivity, sampling strategy, fit-for-purpose validation and interpretation of MRD data alongside clinical and imaging endpoints.
With a focus on real-world execution, this webinar provides practical guidance on selecting assay platforms, defining meaningful thresholds and driving cross-functional alignment across regulatory, clinical pharmacology, biomarker and operations teams. Watch to gain a clearer framework for incorporating MRD into oncology development strategies—and accelerating more confident, data-driven decision-making.
Related Content
Looking for exclusive insight?
